References
1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395(10229):1054–62.
2. Döhla M, Boesecke C, Schulte B, Diegmann C, Sib E, Richter E, et al. Rapid point-of-care testing for SARS-CoV-2 in a community screening setting shows low sensitivity. Public Health. 2020;182:170–2.
3. Arevalo-Rodriguez I, Buitrago-Garcia D, Simancas-Racines D, Zambrano-Achig P, Campo R del, Ciapponi A, et al. False-negative results of initial RT-PCR assays for COVID-19: a systematic review. medRxiv. 2020 (ref 2020.04.16.20066787).
4. NICE. FebriDx for C-reactive protein and Myxovirus virus resistance protein A testing in primary care: A testing in primary care Medtech innovation briefing. 2017. London: NICE.
5. Karim N, Ashraf MZ, Naeem M, Anwar T, Aung H, Mallik S, et al. Utility of FebriDx in early identification of possible COVID19 infection. Res Sq 2020; doi 10.21203/rs.3.rs-25802/v1.
6. Brendish NJ, Poole S, Naidu V V, Mansbridge C, Norton N, Wheeler H, et al. Real-world diagnostic accuracy of a host response point-of-care test in hospitalised patients with suspected COVID-19. Lancet 2020. SSRN pre-print: https://dx.doi.org/10.2139/ssrn.3582747.
7. Cheng MP, Papenburg J, Desjardins M, Kanjilal S, Quach C, Libman M, et al. Diagnostic Testing for Severe Acute Respiratory Syndrome-Related Coronavirus-2: A Narrative Review. Ann Intern Med 2020;13:13.
8. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020; 581: 465–469.
9. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis 2020;28.
10. Guo L, Ren L, Yang S, Xiao M, Chang, Yang F, et al. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). Clin Infect Dis 2020;21.
11. Huang AT, Garcia-Carreras B, Hitchings MDT, Yang B, Katzelnick L, Rattigan SM, et al. A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease. medRxiv 2020 (ref 2020.04.14.20065771).
12. Spiegel M, Weber F. Inhibition of cytokine gene expression and induction of chemokine genes in non-lymphatic cells infected with SARS coronavirus. Virol J. 2006; 29(3):17.
13. Beard K, Chan C, Mills S, Poole S, Brendish N, Tristan William C. Evaluation of the Febridx Host Response Point-of-Care Test to Differentiate Viral From Bacterial Etiology in Adults Hospitalized with Acute Respiratory Illness During Influenza Season. Open Forum Infect Dis. 2019;6(Suppl 2):2019.
14. Sambursky R, Shapiro N. Evaluation of a combined MxA and CRP point-of-care immunoassay to identify viral and/or bacterial immune response in patients with acute febrile respiratory infection. Eur Clin Respir J. 2015;2(1):28245.
15. Self W, Rosen J, Sharp S, Filbin M, Hou P, Parekh A, et al. Diagnostic Accuracy of FebriDx: A Rapid Test to Detect Immune Responses to Viral and Bacterial Upper Respiratory Infections. J Clin Med. 2017; 6(10): 94.
16. Shapiro NI, Self WH, Rosen J, Sharp SC, Filbin MR, Hou PC, et al. A prospective, multi-centre US clinical trial to determine accuracy of FebriDx point-of-care testing for acute upper respiratory infections with and without a confirmed fever. Ann Med. 2018; 50(5):420-429.
17. FIND. SARS-CoV2 diagnostics: performance data. 2020. Available from: https://www.finddx.org/covid-19/dx-data/ [accessed 02/06/2020]